Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update
30 nov. 2022 16h15 HE
|
Synlogic, Inc.
Top-line Phase 1 data in healthy volunteers show that SYNB1353 reduces plasma methionine by consuming methionine in the GI tract SYNB1353 has been granted Orphan Drug Designation (ODD) from the FDA...
Synlogic Reports Third Quarter 2022 Financial Results and Provides Business Update
10 nov. 2022 06h59 HE
|
Synlogic, Inc.
Top-line Phase 2 data for phenylketonuria (PKU) demonstrated robust plasma Phe reduction and high response rate; Phase 3 study initiation planned for H1 2023 Clinical readouts for SYNB1353 for...
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium
25 août 2022 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present a genetic evaluation and an analysis of...
Synlogic Granted FDA Fast Track Designation for SYNB1353 for the Treatment of Homocystinuria (HCU)
23 août 2022 07h00 HE
|
Synlogic, Inc.
CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
Synlogic Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria (HCU)
12 juil. 2022 07h00 HE
|
Synlogic, Inc.
Expected data in H2 2022 brings Synlogic to three clinical readouts this year Third candidate in less than two years to enter the clinic; Reflects productivity of Synthetic Biotic platform ...
Synlogic to Present at the 2022 HCU Network America, Organic Acidemia Association and Propionic Acidemia Foundation Conference
21 juin 2022 07h00 HE
|
Synlogic, Inc.
BETHESDA, Md., June 21, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
Travere Therapeutics Announces Positive Topline Results from the Ongoing Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria
15 déc. 2021 07h00 HE
|
Travere Therapeutics, Inc.
Treatment with highest dose pegtibatinase led to a clinically meaningful 55% mean reduction in total homocysteine from baseline and was generally well-tolerated after 12 weeks of treatment Results...
Retrophin Announces Corporate Name Change to Travere Therapeutics, Inc.
16 nov. 2020 08h00 HE
|
Retrophin, Inc.
New name reflects dedication to patient-inspired mission of identifying, developing and delivering life-changing rare disease therapies Company’s shares to trade under new ticker symbol TVTX on...